ArticleResearch square2026
Oncogenic cell fate decision in breast epithelial cells I: growth factors and mechanisms.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Background: Breast cancer cell heterogeneity and cellular fate are governed by a variety of molecular mechanisms. The LINCS (Library of Integrated Network-based Cellular Signatures) consortium performed multi-omics experiments on normal breast epithelial cells, MCF10a, to deduce temporal mechanisms of regulation and cell state signatures contributing to pro-oncogenic phenotypes. Methods: Normal breast epithelial cells were treated with oncogenic ligands such as EGF, HGF, and OSM, and multi-modal measurements including Reverse phase protein Assay (RPPA), RNA-seq, ATAC-seq, and Cyclic immune-fluorescence (Cyclic-IF) were performed. Result: In our integrated analyses of the data to elucidate mechanisms, contextual functional networks were constructed by integrating protein signaling, transcription factor activity, and gene expression. Phenotypic changes in response to the ligands consisted of cell cycle modifications leading to oncogenic events such as loss of apoptosis and induction of EMT (Epithelial to Mesenchymal Transition). Activation of mTOR was observed with all ligands, which led to the activation of E2F1. Downstream transcriptomic regulation of E2F1 led to an increase in both oncogenic signaling and EMT. Additionally, under OSM treatment, activation of STAT3 facilitated the enhancement of EMT via transcriptomic regulation of JUN and FOS. These findings were further validated using the chromatin changes seen in ATAC-seq and protein localization as seen in Cyclic-IF assay. Conclusion: This analysis provides valuable insights into the mechanisms of transcriptional regulation during oncogenesis in normal breast cells treated with growth factors and can aid in the discovery of novel drug targets and treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.